A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 144 participants.

Also called NCT07091994

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 144 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07091994
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07091994. Randomized; double masking; primary purpose treatment. Start 2026-08-01 (anticipated); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy
Acronym
PRECISE AM
Condition
Ischemic Stroke, Acute
Condition
Active Malignancies
Intervention (Drug)
edaravone dexborneol injection
Intervention (Drug)
Standard therapeutic protocol
Lead sponsor
Nanfang Hospital, Southern Medical University (class: other)

Record details

Record id
cardio:ct-nct07091994
Content hash
a16c5353b0d4d261f0eb55f6257a797e7b5ba0f571c35d168e95425da9795e9f